| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_116fa4406381fc82bb76e8657e68788a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C327-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-197
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-222
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-405
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C335-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0217
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C275-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C243-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-02 |
| filingDate |
2013-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f65e6ac8c9c056586f63e8e785955bca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_189eddd1100625ffa30072369d8b872b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ceb64273775ae4baeb6daded179f425 |
| publicationDate |
2015-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2822957-A1 |
| titleOfInvention |
Peptidomimetic compounds as immunomodulators |
| abstract |
The present invention relates to novel peptidomimetic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them. |
| priorityDate |
2012-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |